Home Cart 0 Sign in  
X

[ CAS No. 1196-57-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1196-57-2
Chemical Structure| 1196-57-2
Chemical Structure| 1196-57-2
Structure of 1196-57-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1196-57-2 ]

Related Doc. of [ 1196-57-2 ]

Alternatived Products of [ 1196-57-2 ]

Product Details of [ 1196-57-2 ]

CAS No. :1196-57-2 MDL No. :MFCD00006722
Formula : C8H6N2O Boiling Point : -
Linear Structure Formula :- InChI Key :FFRYUAVNPBUEIC-UHFFFAOYSA-N
M.W : 146.15 Pubchem ID :14526
Synonyms :
2-Quinoxalinol;Quinoxalin-2-one
Chemical Name :2-Quinoxalinol

Calculated chemistry of [ 1196-57-2 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.56
TPSA : 46.01 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.3 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.52
Log Po/w (XLOGP3) : 1.25
Log Po/w (WLOGP) : 1.34
Log Po/w (MLOGP) : 0.66
Log Po/w (SILICOS-IT) : 1.5
Consensus Log Po/w : 1.25

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.21
Solubility : 0.909 mg/ml ; 0.00622 mol/l
Class : Soluble
Log S (Ali) : -1.81
Solubility : 2.24 mg/ml ; 0.0153 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.73
Solubility : 0.272 mg/ml ; 0.00186 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.77

Safety of [ 1196-57-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1196-57-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1196-57-2 ]
  • Downstream synthetic route of [ 1196-57-2 ]

[ 1196-57-2 ] Synthesis Path-Upstream   1~34

  • 1
  • [ 1196-57-2 ]
  • [ 5424-05-5 ]
Reference: [1] Organic Letters, 2017, vol. 19, # 7, p. 1788 - 1791
  • 2
  • [ 1196-57-2 ]
  • [ 5424-05-5 ]
Reference: [1] Journal of the Chemical Society, 1945, p. 622,625
[2] Patent: US2537870, 1946, ,
  • 3
  • [ 1196-57-2 ]
  • [ 1448-87-9 ]
YieldReaction ConditionsOperation in experiment
93% With trichlorophosphate In toluene for 1 h; Reflux The chlorination of the 2-hydroxy quinoxaline was carried out in neat POCl3 (2.3 eqs) at reflux for an hour and produced the 2-chloro-quinoxaline (1D-008) in very good yield. This chemistry was tested on 100 g scale and afforded typically 103-105 g (98-99percent). A quick filtration through a Pad of silica of the crude reaction mixture resulted in clean material (99percent pure by LCMS). This reaction has beenscaled up to 600 g.
Reference: [1] Patent: US2017/143706, 2017, A1, . Location in patent: Paragraph 0050; 0106; 0107
[2] Helvetica Chimica Acta, 2001, vol. 84, # 5, p. 1112 - 1118
[3] Heterocycles, 2005, vol. 65, # 1, p. 181 - 185
[4] Heterocycles, 2006, vol. 68, # 9, p. 1973 - 1979
[5] Journal of the Chemical Society, 1945, p. 622,625
[6] Journal of the Chemical Society, 1957, p. 3236,3237
[7] Bulletin de la Societe Chimique de France, 1959, p. 1793,1796
[8] Patent: US2537870, 1946, ,
[9] Heterocycles, 1985, vol. 23, # 10, p. 2603 - 2611
[10] Chemistry Letters, 1984, p. 323 - 326
[11] Heterocycles, 2012, vol. 86, # 2, p. 1583 - 1590
  • 4
  • [ 1196-57-2 ]
  • [ 1448-87-9 ]
YieldReaction ConditionsOperation in experiment
81% at 110℃; for 12 h; Inert atmosphere The 2.000g2-hydroxy quinoxaline in 20mL phenylphosphonic dichloride, under nitrogen conditions, 110 ° C reflux 12h. The reaction was monitored by TLC. After completion of the reaction, the reaction solution was cooled to room temperature, poured into ice water slowly with constant stirring. product After precipitation, filtration, washing, drying, you can get 1.830g2- chloro quinoxaline (intermediate II-1), a yield of 81percent.
75% for 2 h; Reflux Place 2-hydroxyquinoxaline (2 g) and phosphorus oxychloride (20 mL) in 100 mLIn a three-neck flask, add 5 drops of DMF, and transfer the system to reflux for 2h.In a 500 mL beaker, add an appropriate amount of ice water. White solids precipitated,Yield 75percent.
75% for 2 h; Reflux 2-hydroxyquinoxaline (2 g) and phosphorus oxychloride (20 mL) were placed in 100 mL of threeStir in the bottle, add 5 drops of DMF, reflux for 2 h, transfer the system to a 500 mL beaker, and add an appropriate amount of ice water. Precipitating whiteSolid, yield 75percent
35% at 79 - 100℃; for 0.25 h; General procedure: 0.13 mL of N,N-dimethylformamide was added dropwise to a slurry monohydroxy quinoxaline 1d-e (0.5g, 3.1 mmol) and thionyl chloride (0.73 g, 6.2 mmol) in 1-chlorobutane(5 mL). The resulting reaction mixture was refluxed for 15min., and then evaporated to dryness under reduced pressure to leave a solid. The residue was taken up in a minimum of CH2Cl2, filtered and washed with CH2Cl2. Concentration then give the halogenated derivatives.

Reference: [1] Molecules, 2012, vol. 17, # 4, p. 4533 - 4544
[2] ChemMedChem, 2015, vol. 10, # 1, p. 193 - 206
[3] Patent: CN103787992, 2016, B, . Location in patent: Paragraph 0079-0082
[4] Patent: CN107602539, 2018, A, . Location in patent: Paragraph 0043
[5] Patent: CN108530435, 2018, A, . Location in patent: Paragraph 0015; 0017
[6] Tetrahedron Letters, 1999, vol. 40, # 42, p. 7477 - 7478
[7] Synthetic Communications, 2005, vol. 35, # 15, p. 1983 - 1987
[8] Synthetic Communications, 2011, vol. 41, # 23, p. 3532 - 3540
[9] Chemistry - A European Journal, 2009, vol. 15, # 19, p. 4857 - 4864
[10] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4508 - 4522
[11] Revue Roumaine de Chimie, 2017, vol. 62, # 12, p. 903 - 906
[12] Journal of Physical Organic Chemistry, 1994, vol. 7, # 10, p. 545 - 550
[13] Journal of Organic Chemistry, 2003, vol. 68, # 5, p. 2054 - 2057
[14] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 24, p. 6723 - 6728
[15] Patent: US4076806, 1978, A,
[16] Medicinal Chemistry Research, 2013, vol. 22, # 4, p. 1660 - 1673
  • 5
  • [ 1196-57-2 ]
  • [ 1448-87-9 ]
  • [ 877078-00-7 ]
Reference: [1] Phosphorus, Sulfur and Silicon and the Related Elements, 2005, vol. 180, # 8, p. 1795 - 1807
  • 6
  • [ 61645-34-9 ]
  • [ 1448-87-9 ]
  • [ 1196-57-2 ]
Reference: [1] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1983, p. 217 - 220[2] Khimiya Geterotsiklicheskikh Soedinenii, 1983, vol. 19, # 2, p. 265 - 267
  • 7
  • [ 6935-29-1 ]
  • [ 1448-87-9 ]
  • [ 5448-43-1 ]
  • [ 62163-09-1 ]
  • [ 1196-57-2 ]
Reference: [1] Tetrahedron, 1989, vol. 45, # 24, p. 7795 - 7804
  • 8
  • [ 6935-29-1 ]
  • [ 7677-24-9 ]
  • [ 91-19-0 ]
  • [ 1448-87-9 ]
  • [ 23088-24-6 ]
  • [ 77130-32-6 ]
  • [ 1196-57-2 ]
  • [ 7483-33-2 ]
Reference: [1] Tetrahedron, 1989, vol. 45, # 24, p. 7795 - 7804
  • 9
  • [ 6935-29-1 ]
  • [ 1448-87-9 ]
  • [ 5448-43-1 ]
  • [ 62163-09-1 ]
  • [ 1196-57-2 ]
Reference: [1] Tetrahedron, 1989, vol. 45, # 24, p. 7795 - 7804
  • 10
  • [ 6935-29-1 ]
  • [ 7677-24-9 ]
  • [ 5448-43-1 ]
  • [ 62163-09-1 ]
  • [ 1196-57-2 ]
  • [ 7483-33-2 ]
Reference: [1] Tetrahedron, 1989, vol. 45, # 24, p. 7795 - 7804
  • 11
  • [ 91-19-0 ]
  • [ 17056-99-4 ]
  • [ 112259-29-7 ]
  • [ 1196-57-2 ]
Reference: [1] Journal of the Chemical Society, Chemical Communications, 1987, p. 1722 - 1724
[2] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1993, # 9, p. 1065 - 1072
  • 12
  • [ 1196-57-2 ]
  • [ 6640-47-7 ]
Reference: [1] Helvetica Chimica Acta, 1994, vol. 77, # 6, p. 1549 - 1556
  • 13
  • [ 1196-57-2 ]
  • [ 18671-97-1 ]
Reference: [1] Chemistry Letters, 1984, p. 323 - 326
  • 14
  • [ 1196-57-2 ]
  • [ 2213-63-0 ]
Reference: [1] Helvetica Chimica Acta, 1994, vol. 77, # 6, p. 1549 - 1556
[2] Chemistry Letters, 1984, p. 323 - 326
[3] Chemistry Letters, 1984, p. 323 - 326
  • 15
  • [ 1196-57-2 ]
  • [ 10026-13-8 ]
  • [ 2213-63-0 ]
Reference: [1] Chemische Berichte, 1908, vol. 41, p. 800
  • 16
  • [ 1196-57-2 ]
  • [ 55687-02-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1981, vol. 24, # 1, p. 93 - 101
[2] Patent: WO2011/4276, 2011, A1,
  • 17
  • [ 1196-57-2 ]
  • [ 55687-02-0 ]
Reference: [1] Patent: US2012/230951, 2012, A1,
[2] Patent: US2015/368278, 2015, A1,
  • 18
  • [ 1196-57-2 ]
  • [ 89891-65-6 ]
Reference: [1] Patent: WO2011/26579, 2011, A1,
[2] Patent: US2013/53384, 2013, A1,
[3] Patent: WO2013/112950, 2013, A2,
[4] Patent: WO2014/75077, 2014, A1,
[5] Patent: WO2016/97918, 2016, A1,
[6] Patent: WO2013/40515, 2013, A1,
  • 19
  • [ 1196-57-2 ]
  • [ 89891-65-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4735 - 4751
[2] Patent: US2013/190307, 2013, A1,
[3] Patent: WO2014/151147, 2014, A1,
[4] Patent: US2015/30588, 2015, A1,
[5] Patent: US9295673, 2016, B2,
[6] Patent: WO2017/32840, 2017, A1,
[7] Patent: WO2012/34526, 2012, A1,
  • 20
  • [ 1196-57-2 ]
  • [ 212327-11-2 ]
Reference: [1] Patent: WO2017/32840, 2017, A1,
  • 21
  • [ 34836-97-0 ]
  • [ 1196-57-2 ]
  • [ 2427-71-6 ]
Reference: [1] Heterocycles, 1985, vol. 23, # 1, p. 143 - 151
  • 22
  • [ 1196-57-2 ]
  • [ 2427-71-6 ]
Reference: [1] Chemistry Letters, 1984, p. 323 - 326
  • 23
  • [ 34836-97-0 ]
  • [ 1196-57-2 ]
  • [ 2427-71-6 ]
  • [ 89938-22-7 ]
  • [ 6639-79-8 ]
Reference: [1] Heterocycles, 1985, vol. 23, # 1, p. 143 - 151
  • 24
  • [ 1196-57-2 ]
  • [ 25652-34-0 ]
  • [ 6272-25-9 ]
Reference: [1] Patent: US5153196, 1992, A,
  • 25
  • [ 1196-57-2 ]
  • [ 6272-25-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 18, p. 3319 - 3324
[2] Bioorganic Chemistry, 2014, vol. 56, p. 16 - 26
  • 26
  • [ 1196-57-2 ]
  • [ 6272-25-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 5, p. 1403 - 1407
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4508 - 4522
  • 27
  • [ 1196-57-2 ]
  • [ 55686-94-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4508 - 4522
[2] Journal of Medicinal Chemistry, 2016, vol. 59, # 13, p. 6169 - 6186
[3] Journal of the Brazilian Chemical Society, 2017, vol. 28, # 10, p. 1874 - 1878
  • 28
  • [ 1196-57-2 ]
  • [ 89898-96-4 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2007, vol. 55, # 2, p. 255 - 267
[2] Yakugaku Zasshi, 1959, vol. 79, p. 658[3] Chem.Abstr., 1959, p. 21979
  • 29
  • [ 1196-57-2 ]
  • [ 25652-34-0 ]
Reference: [1] Bioorganic Chemistry, 2014, vol. 56, p. 16 - 26
[2] Chemical and Pharmaceutical Bulletin, 2007, vol. 55, # 2, p. 255 - 267
[3] Journal of Medicinal Chemistry, 1992, vol. 35, # 18, p. 3319 - 3324
[4] Patent: US2009/264426, 2009, A1, . Location in patent: Page/Page column 43
[5] Patent: WO2007/29847, 2007, A1, . Location in patent: Page/Page column 66
  • 30
  • [ 1196-57-2 ]
  • [ 82031-32-1 ]
YieldReaction ConditionsOperation in experiment
88% at 20℃; for 12 h; [0288] To a solution of quinoxalin-2(lH)-one (54.64 g, 374 mmol, 1.0 eq.) in HOAc (1000 mL) was added a solution of Br2 (19.18 mL, 374 mmol, 1.0 eq.) in HOAc (200 mL) dropwise. The resulting mixture was stirred at rt for 12 h, then poured into ice- water. The precipitate was collected by filtration and dried to afford 7-bromoquinoxalin-2(lH)-one as an off-white solid (74 g, 88percent).
88% at 20℃; for 12 h; To a solution of   quinoxalin-2(1H)-one (54.64 g, 374 mmol, 1.0 eq.) in   HOAc (1000 mL) was added a solution of   Br2 (19.18 mL, 374 mmol, 1.0 eq.) in HOAc (200 mL) dropwise. The resulting mixture was stirred at rt for 12 h, then poured into ice-water. The precipitate was collected by filtration and dried to afford   7-bromoquinoxalin-2(1H)-one as an off-white solid (74 g, 88percent).
88% at 20℃; for 12 h; Example 1: Preparation of -(3-fluorophenyl)-3-(3-((3-morpholinoquinoxalin-6-yl)oxy)phenyl)urea 1 -(3-fluorophenyl)-3-(3-((3-morpholinoquinoxalin-6-yl)oxy)phenyl)urea [0186] To a solution of quinoxalin-2(lH)-one (54.64 g, 374 mmol, 1.0 eq.) in HOAc (1000 mL) was added a solution of Br2 (19.18 mL, 374 mmol, 1.0 eq.) in HOAc (200 mL) dropwise. The resulting mixture was stirred at room temperature for 12 h, then poured into ice-water. The precipitate was collected by filtration and dried to afford 7-bromoquinoxalin-2(lH)-one (74 g, 88percent).
88% With bromine In acetic acid at 20℃; [0174] To a solution of quinoxalin-2(lH)-one (54.64 g, 374 mmol, 1.0 eq.) in HOAc (1000 mL) was added a solution of Br2 (19.18 mL, 374 mmol, 1.0 eq.) in HOAc (200 mL)dropwise. The resulting mixture was stirred at r.t. for 12 h, then poured into ice-water. The precipitate was collected by filtration and dried to afford 7-bromoquinoxalin-2(lH)-one as an off-white solid (74 g, 88percent yield).
73% at 20℃; for 48 h; Inert atmosphere Example 69: 3-oxo-3.,4-dihvdro-2H-benzo[l,41thiazine-6-carboxylic acid {l-[2-(7- methylsulfanyl-quinoxalin-2-yloxy)-ethyll-piperidin-4-yl}-amide: Preparation of 7-bromo-iH-quinoxalin-2-one: Bromine (7.36 mL, 147 mmol, 1.05 eq) is added at room temperature to a stirred suspension of iH-quinoxalin-2-one (20 g, 137 mmol, 1.0 eq) in acetic acid (400 mL). After 48 hours stirring at room temperature, the reaction mixture is poured into ice (500 mL) and the resulting precipitate is collected by filtration, washed with water and ethyl acetate to afford7-bromo-iH-quinoxalin-2-one as a yellow solid (29.4 g, 73percent yield). 1H-NMR (400 MHz, DMSO-t/6) δ ppm: 12.44 (br, IH), 8.17 (s, IH), 7.69 (d, J = 8.8 Hz, IH), 7.44 (m, 2H).MS m/z (+ESI): 225.1 [M+H]+.
66% With bromine In acetic acid at 20℃; for 19.5 h; Step B: Preparation of 7-bromo-1H- uinoxalin-2-oneTo a stirred solution of 1 H-quinoxalin-2-one (50 g, 342.5 mmol) in glacial acetic acid (2500 ml.) was added bromine (54.7 g, 342.5 mmol in 120 ml_ acetic acid) over a period of 1.5 h at rt. After 18 h stirring, the mixture was slowly poured into 2000 ml_ water and stirred for 1 h at rt. The precipitate was filtered and the residue was washed with water and dried to give 7-bromo-1 H- quinoxalin-2-one as an off-white solid (51 g, 66percent): 1H-NMR (300 MHz, d6- DMSO): δ = 12.42 (1 H, s), 8.19 (1 H, s), 7.75 (1 H, d), 7.44 (2H, m) ppm.
58% at 0℃; for 2 h; To a cooled 0 °C solution of quinoxalin-2(1 /-/)-one (I-70) (50 g, 342.2 mmol) in acetic acid (800 ml_) was added in a dropwise manner a solution of bromine (32 ml_) in acetic acid (200 ml_) over a period of 30 min. Solids formed within the reaction upon addition of bromine, and the reaction was allowed to stir slowly for a further 90 min. The solid was filtered, washed with MeOH and ether, and dried under high vacuum to afford 7-bromoquinoxalin-2(1 /-/)-one (1-71) (45 g, 58percent) as a white solid. LCMS (APCI), m/z 224.1 [M + H]+; 1H NMR (400 MHz, DMSO-c/6J 8 ppm 12.46 (s, 1 H), 8.16 - 8.18 (m, 1 H), 7.69 - 7.72 (d, 1 H), 7.44 - 7.46 (m, 2 H).
26% at 20℃; for 1.5 h; Bromine (3.56 mL, 68.63 mmol) was slowly added to a solution of quinoxalin-2(lH)-one (10.03 g, 68.63 mmol) in 0.1M acetic acid (686.3 mL). The reaction mixture was stirred at ambient temperature for 1.5 hours. The resulting solids were collected by filtration and washed with hexanes to afford 7-bromoquinoxalin-2(lH)-one (4.02 g, 17.86 mmol, 26.0percent yield). 1H NMR (400 MHz, (CD3)2SO) δ = 12.466 (s, 1H), 8.191 (s, 1H), 7.724-7.700 (d, 1H), 7.470-7.444 (m, 2H).

Reference: [1] Patent: WO2013/40515, 2013, A1, . Location in patent: Paragraph 0288
[2] Patent: US2013/53384, 2013, A1, . Location in patent: Paragraph 0470; 0471; 0472
[3] Patent: WO2013/112950, 2013, A2, . Location in patent: Paragraph 0186
[4] Patent: WO2014/75077, 2014, A1, . Location in patent: Paragraph 0174
[5] Patent: WO2010/84152, 2010, A1, . Location in patent: Page/Page column 111-112
[6] Patent: WO2011/26579, 2011, A1, . Location in patent: Page/Page column 56-57
[7] Patent: WO2016/97918, 2016, A1, . Location in patent: Page/Page column 73
[8] Patent: WO2012/118492, 2012, A1, . Location in patent: Page/Page column 72
[9] Journal of Medicinal Chemistry, 1981, vol. 24, # 1, p. 93 - 101
[10] Patent: WO2004/50659, 2004, A1, . Location in patent: Page 48-49
  • 31
  • [ 1196-57-2 ]
  • [ 82031-32-1 ]
Reference: [1] Patent: US2008/293706, 2008, A1, . Location in patent: Page/Page column 26; 27
  • 32
  • [ 1196-57-2 ]
  • [ 55687-34-8 ]
YieldReaction ConditionsOperation in experiment
40% With bromine; silver sulfate In tetrachloromethane; sulfuric acid at 20 - 50℃; The quinoxalin-2(1H)-one (14.6 g, 0.1 mol, Aldrich, cat. no. 260517) and silver sulphate (15.6 g, 0.05 mol) were dissolved in cone. Sulfuric acid (100 ml) at 200C. Bromine (5.2 ml, 0.1 mol) was added and the reaction mixture was stirred vigorously for 24 hours. The reaction mass was then diluted with carbon tetrachloride (100 ml_), and this was heated at 5O0C. The reaction mass was then filtered and the filtrate was poured into ice cold water and stirred for 30 minutes to obtain a precipitate. The precipitate was filtered and the solid material was dried in vacuo to afford the title product (9.0 g, 40percent).
Reference: [1] ChemMedChem, 2014, vol. 9, # 7, p. 1378 - 1386
[2] Patent: WO2010/136755, 2010, A1, . Location in patent: Page/Page column 46; 47
[3] Journal of Medicinal Chemistry, 1981, vol. 24, # 1, p. 93 - 101
[4] Patent: US2007/173508, 2007, A1, . Location in patent: Page/Page column 84
[5] Patent: WO2011/4276, 2011, A1, . Location in patent: Page/Page column 106
  • 33
  • [ 1196-57-2 ]
  • [ 82019-32-7 ]
Reference: [1] Patent: WO2012/118492, 2012, A1,
  • 34
  • [ 1196-57-2 ]
  • [ 212327-10-1 ]
Reference: [1] Patent: WO2012/118492, 2012, A1,
[2] Patent: WO2014/75077, 2014, A1,
[3] Patent: WO2013/40515, 2013, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1196-57-2 ]

Alcohols

Chemical Structure| 18591-57-6

[ 18591-57-6 ]

5,6-Diphenylpyrazin-2-ol

Similarity: 0.81

Chemical Structure| 20721-18-0

[ 20721-18-0 ]

6-Methylpyrazin-2-ol

Similarity: 0.81

Chemical Structure| 488834-75-9

[ 488834-75-9 ]

Quinoxalin-6-ylmethanol

Similarity: 0.71

Chemical Structure| 60187-00-0

[ 60187-00-0 ]

3,5-Dimethylpyrazin-2-ol

Similarity: 0.70

Chemical Structure| 55687-34-8

[ 55687-34-8 ]

6-Bromoquinoxalin-2(1H)-one

Similarity: 0.69

Related Parent Nucleus of
[ 1196-57-2 ]

Quinoxalines

Chemical Structure| 6333-43-3

[ 6333-43-3 ]

2,3-Dimethoxyquinoxaline

Similarity: 0.75

Chemical Structure| 488834-75-9

[ 488834-75-9 ]

Quinoxalin-6-ylmethanol

Similarity: 0.71

Chemical Structure| 55687-34-8

[ 55687-34-8 ]

6-Bromoquinoxalin-2(1H)-one

Similarity: 0.69

Chemical Structure| 5424-05-5

[ 5424-05-5 ]

Quinoxalin-2-amine

Similarity: 0.67

Chemical Structure| 212327-10-1

[ 212327-10-1 ]

7-Bromo-2-methoxyquinoxaline

Similarity: 0.64